Full results of the CANVAS trial are expected to be released in June at the American Diabetes Association.
The FDA today issued a new boxed warning for canagliflozin, the type 2 diabetes (T2D) therapy sold as Invokana (and in a combination, Invokamet), due to risk of leg and foot amputation risk.
In a statement, the FDA said the warning is due to the results of 2 trials, CANVAS (Canagliflozin Cardiovascular Assessment Study) and CANVAS-R (A Study of the Effects of Canagliflozin on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus), which showed that leg and foot amputations were twice as likely in patients taking canagliflozin as those randomly assigned a placebo.
In the patients studied, amputations of the toe and middle of the foot were most common, but amputations of the leg, both above and below the leg, were also seen. The boxed warning follows a May 18, 2016, safety alert.
Canagliflozin is a sodium glucose co-transporter-2 (SGLT2) inhibitor, which works by targeting the protein that reabsorbs glucose in the renal system and causes excess sugar to be expelled in the urine.
The FDA urges physicians considering prescribing canagliflozin to consider factors that could lead to amputation, such as prior history, peripheral vascular disease, neuropathy, and diabetic foot ulcers.
Janssen, the maker of canagliflozin, issued a statement in response to today's action, which read in part:
"The finding of increased risk of lower-limb amputation—primarily of the toe and forefoot—observed last year in the interim safety analysis of the CANVAS study of patients at high risk for cardiovascular events or with established CV disease, was confirmed in the final analysis of CANVAS and CANVAS-R.
The U.S. FDA shared the initial observation last May in a Drug Safety Communication, and Janssen shared it directly with Heath Care Professionals. While the incidence was low, the highest incidence of amputations across all treatments was seen in patients with prior amputation.
At Janssen, patient safety is our highest priority. We are working with FDA to include this information in the prescribing information for canagliflozin and look forward to the presentation of the full CANVAS Program results at the American Diabetes Association Scientific Sessions in June."
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen
What We’re Reading: ACA Perception; FDA Blood Sugar Warning; AI and Physician Burnout
February 22nd 2024More than half of US adults have a favorable view of the Affordable Care Act (ACA); smartwatches and rings that claim to measure blood sugar levels without piercing the skin could be dangerous and should be avoided; many believe artificial intelligence (AI) could be the solution to physician burnout.
Read More
Advancements in Diabetes Technology: Coverage, Challenges, and Pregnancy Considerations
February 15th 2024Expert interviews highlight advancements and challenges in diabetes care technology, including automated insulin delivery systems and continuous glucose monitors, as well as improvements in insurance coverage.
Read More